
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
The Readout Loud
00:00
Navigating Trials and Treatments in Obesity
This chapter analyzes Recursion's clinical trial results and their influence on investor sentiment while exploring the evolving landscape of obesity treatments, particularly focusing on amylin. It also discusses the challenges faced by Amylin Pharmaceuticals and highlights promising developments from Zealand that may enhance patient outcomes.
Transcript
Play full episode